Background and Challenges

The surge in neurodegenerative diseases highlights the critical role of excessive immune cell activation within the brain. Specifically, microglia, through the NF-κB signaling pathway, continuously release pro-inflammatory cytokines like IL-1β and TNF-α, leading to neuronal death. However, previous studies primarily focused on acute injury, failing to fully elucidate the mechanisms linking chronic neuronal loss and synaptic dysfunction. A key gap lies in understanding how the long-term interplay between microglia and astrocytes affects blood-brain barrier (BBB) permeability and facilitates peripheral immune cell infiltration. Activation of the TLR4-MyD88 pathway triggers a cascade involving MAPK and JNK, promoting the expression of inflammatory genes COX-2 and iNOS. Evidence suggests this process accelerates neurofibrillary tangle formation and amyloid-β accumulation in Alzheimer's disease (AD) and Parkinson's disease (PD). When these complex signaling networks operate simultaneously, synaptic potentiation becomes unstable, leading to a vicious cycle culminating in memory impairment and motor dysfunction. Therefore, a pressing need exists to clarify how microglia-astrocyte interactions and peripheral immune cell infiltration contribute to neurodegeneration and to identify specific molecular targets for intervention.

Research Methods and Key Findings

The research team combined single-cell RNA-seq and spatial transcriptomics to precisely map the transcriptional profiles of microglia and astrocytes in different brain regions. This revealed that microglia with activated NLRP3 inflammasome complexes excessively secrete IL-18 and ASC-caspase-1. Using systems biology modeling, they simulated the feedback loops between NF-κB, STAT3, and the PI3K-AKT pathway. The simulation predicted that when the cytokine storm exceeds a certain threshold, the expression of Claudin-5 and Occludin in the BBB is drastically reduced, a prediction confirmed by actual experiments. Furthermore, they discovered that when peripheral immune cells, specifically CD4⁺ T cells, enter the brain tissue via the CXCL10/CXR3 axis, the CD36 receptor on the surface of microglia promotes fatty acid metabolism, increasing ROS (reactive oxygen species) production. This explains the simultaneous occurrence of oxidative stress and inflammation. These data provide comprehensive evidence for the existence of a common 'inflammation-metabolism-neuronal loss' triad in various diseases, including Alzheimer's, ALS, and Huntington's disease, and serve as an important guide for exploring new therapeutic targets.

Therapeutic Opportunities and Current Strategies

The researchers presented preclinical data showing that small-molecule drugs, such as the NLRP3 inhibitor Diazepam, block caspase-1 activity in microglia, reducing IL-1β release by more than 60%. This is being rapidly translated into clinical application through collaboration with BioInflammation, a biotechnology company currently conducting a Phase II clinical trial. Furthermore, reports indicate that activating the TREM2 gene through CRISPR-Cas9-based gene editing restores the phagocytic function of microglia, contributing to the removal of amyloid-β plaques. The FDA is currently reviewing this approach for accelerated approval. A drug delivery system combining nanoparticles (LNP) and blood-brain barrier penetrating peptides (TBP) is designed to simultaneously release COX-2 inhibitors and antioxidants (N-acetylcysteine) into the brain, demonstrating fourfold higher efficacy compared to conventional oral administration. In terms of lifestyle interventions, accumulating clinical data suggest that restricting a high-fat diet and engaging in regular aerobic exercise promotes M2 (anti-inflammatory) polarization of microglia, suggesting that integrated management programs may soon be included in standard treatment.

Future Implications and Prospects

A precision medicine platform is expected to be established, monitoring inflammatory biomarkers such as GFAP, sTREM2, and kynurenine pathway metabolites (quinolinate) in real-time. This will enable personalized drug combinations tailored to individual patient signaling profiles. Simulation results indicate that systems-level mathematical models and AI-based predictive algorithms can simulate treatment response, potentially reducing failure rates in clinical trials by more than 30%. This is expected to have a direct impact on reducing research costs and accelerating the launch of new drugs for pharmaceutical companies. Furthermore, gene therapies targeting VEGF-A and Angiopoietin-1, aimed at regenerating the blood-brain barrier, are currently in Phase I clinical trials and show a favorable safety profile, suggesting that they may play a key role in improving drug delivery efficiency by restoring the BBB in the future. Ultimately, if a 'multi-target therapy package' that comprehensively controls the inflammation-metabolism-neural network can be integrated into standard treatment protocols, it will significantly slow the progression of diseases such as Alzheimer's, offering new hope to patients and their families.